Industry News
Biotechnology Industry News
Japanese conglomerate Asahi Kasei…
Japanese conglomerate Asahi Kasei is acquiring Aicuris in a $920 million deal that will allow Asahi to add approved and investigational assets designed to treat and protect against viral infections in immunocompromised individuals.
The federal government is pledging…
The federal government is pledging as much as $144 million to anti-aging research over the next five years through the Advanced Research Projects Agency for Health (ARPA-H), a subject area previously named as a priority
Boehringer is banking on the…
Boehringer is banking on the program offering a new oral and precision approach to modulating disease-driving immune cells.
After dumping its sole remaining…
After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.
Like Merck & Co.’s PAH drug…
Like Merck & Co.’s PAH drug Winrevair—which brought in $1.4 billion last year—35Pharma's HS235 targets the activin receptor signaling pathway.
With its cash cache set to run out…
With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. The immuno-oncology outfit is weighing
Harbour BioMed is setting sail as…
Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion.
The FDA has ordered MacroGenics to…
The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotech’s lead candidate lorigerlimab following severe side effects that led to one patient death.
Following the launch of its Wegovy…
Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio.
A year after Abcuro raised $200…
A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has flunked all its main goals.
Novo Nordisk and its Chinese…
Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it tries
GSK is continuing to bolster its…
GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies.
Protara Therapeutics has touted a…
Protara Therapeutics has touted a 66% complete response rate for its cell therapy among certain bladder cancer patients as “impressive,” despite this rate halving at the 12-month mark.
Galapagos took a 228 million euro…
Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of
Slate Medicines has emerged with…
Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent migraines, an area where others—such as Eli Lilly and Amgen—have previously failed.
The average upfront value for a…
The average upfront value for a licensing deal between a Western biopharma company and its Chinese counterpart increased from $52 million to $172 million between 2022 and early 2026, according to data shared with Fierce
Astellas is aiding Vir…
Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager for prostate cancer.
After teasing a new regulatory…
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, like the one
Rome-based Angelini Pharma has…
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 million in milestone payments for the
A phase 3 study of Gossamer…
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension has missed its primary endpoint, triggering a 77% crash in the biotech’s share price.